reason report
modest chang number doesnt chang invest thesi
bottom line make sever chang model
includ increas sale restasi sinc product
still gone gener still assum goe gener next month
decreas sale base manag guidanc
annual sale due today announc allergan suspend
sale textur breast implant tissu expand ce mark
countri request french regul decreas sale
canasa aggress op recent launch
gener still assum share buy-back
lower stock price chang aggreg increas ep
lower ep lower ep
chang dont chang posit view stock
think hit base breast implant news provid
buy opportun investor investor sentiment even
go today bad seen name
past year clearli increment neg event
would expect consensu number come dime
howev key year support thesi increas
visibl botox durabl expect materi
neg impact inject cgrp botox migrain
toxin botox cosmet pipelin
expect long-term safeti data present medic meet
oral cgrp ubrogep acut migrain vraylar bipolar depress
approv bimatoprost sr phase data studi glaucoma
rapastinel phase data adjunct studi major depress
sotp cash flow
discount rate
net debt total capit
year price history/av daili volume mil
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
invest thesi four-fold
manag final re-bas number growth expect credibl level balanc
sheet becom less focu allow investor focu key driver
underli growth base busi under-appreci investor driven three
franchis medic aesthet emerg market vraylar
pipelin valu stock given base busi growth assumpt valu base
busi includ adjust
expect multipl expans investor increasingli appreci allergan durabl asset
increas share busi today almost compani
pt base sotp base busi plu pipelin discount rate
new competit impact botox expect
neurosci pipelin fail materi expect
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori allergan plc
leerink place outperform rate juli
creat bluematrix
pt base sotp base busi plu pipelin discount rate
risk valuat
new competit impact botox expect
neurosci pipelin fail materi expect
rate price target histori
leerink place outperform rate novemb
creat bluematrix
use weight averag ev/ebitda multipl ebitda deriv price target
risk valuat
gener advair may get approv commerci uptak biosimilar may take longer anticip
growth ou market may slower expect market penetr gener copaxon may improv
biosimilar neulasta may slower estim
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
